Hue V. Reardon
A5031100776- Cancer Immunotherapy and Biomarkers
- Immunotherapy and Immune Responses
- Cancer Genomics and Diagnostics
- Neuroblastoma Research and Treatments
- Lung Cancer Research Studies
- Epigenetics and DNA Methylation
- Cancer Research and Treatments
- CAR-T cell therapy research
- Genomics and Phylogenetic Studies
- Cancer therapeutics and mechanisms
- Gene expression and cancer classification
- Immune Cell Function and Interaction
Frederick National Laboratory for Cancer Research
2020-2023
Leidos (United States)
2021
Leidos Biomedical Research Inc. (United States)
2021
We perform an immunogenomics analysis utilizing whole-transcriptome sequencing of 657 pediatric extracranial solid cancer samples representing 14 diagnoses, and additionally utilize transcriptomes 131 cell lines 147 normal tissue for comparison. describe patterns infiltrating immune cells, T receptor (TCR) clonal expansion, translationally relevant checkpoints. find that tumor-infiltrating lymphocytes TCR counts vary widely across types within each diagnosis, notably are significantly...
Abstract Children with treatment-refractory or relapsed (R/R) tumors face poor prognoses. As the genomic underpinnings driving R/R disease are not well defined, we describe here and transcriptomic landscapes of solid from 202 patients enrolled in Beat Childhood Cancer Consortium clinical trials. Tumor mutational burden (TMB) was elevated relative to untreated at diagnosis, one-third classified as having a pediatric high TMB. Prior chemotherapy exposure influenced landscape these tumors, more...
The Annotation, Visualization and Impact Analysis (AVIA) is a web application combining multiple features to annotate visualize genomic variant data. Users can investigate functional significance of their genetic alterations across samples, genes pathways. Version 3.0 AVIA offers filtering options through interactive charts by linking disease relevant data sources. Newly incorporated services include gene, sample level reporting, literature correlations among impacted genes, comparative...
<div>Abstract<p>Children with treatment-refractory or relapsed (R/R) tumors face poor prognoses. As the genomic underpinnings driving R/R disease are not well defined, we describe here and transcriptomic landscapes of solid from 202 patients enrolled in Beat Childhood Cancer Consortium clinical trials. Tumor mutational burden (TMB) was elevated relative to untreated at diagnosis, one-third classified as having a pediatric high TMB. Prior chemotherapy exposure influenced landscape...
<p>Table S1. Extended Cohort Annotations. Table S2. Mutational Signatures. S3. GISTIC Copy Number Analysis. S4. Somatic Variants in Relapsed/Refractory Childhood Solid Tumors (n=184 Patients with T/N WES). S5. Clinvar Pathogenic and Likely Germline Tumors(n=184 S6. Gene Lists. S7. Log2(TPM+1) Values for the 2,199 Most Variable Genes Expressed Across of RNA-seq (n=245). S8. Differential Expression Analysis Among Clusters. S9. Filtered COSMIC, Transcription Factors Potential Drug Targets...
<p>GISTIC Analysis of 184 Relapsed and Refractory Childhood Solid Tumors.</p>
<p>Neoantigen Landscape in Relapsed and Refractory Childhood Solid Tumors.</p>
<p>Most Variably Expressed Genes in Relapsed and Refractory Childhood Solid Tumors.</p>
<p>Additional Longitudinal Analysis of Relapsed and Refractory Childhood Solid Tumors.</p>
<p>Consensus Matrix of the GSVA Enrichment Scores Computed for 50 Hallmark Gene Sets. xCell Immune Score Values by Cluster.</p>
<p>Significantly Differentially Expressed Transcription Factors and Drug Targets in Relapsed Refractory Childhood Solid Tumors.</p>
<p>Significantly Differentially Expressed Transcription Factors and Drug Targets in Relapsed Refractory Childhood Solid Tumors.</p>
<p>Consensus Matrix of the GSVA Enrichment Scores Computed for 50 Hallmark Gene Sets. xCell Immune Score Values by Cluster.</p>
<p>Most Variably Expressed Genes in Relapsed and Refractory Childhood Solid Tumors.</p>
<p>Table S1. Extended Cohort Annotations. Table S2. Mutational Signatures. S3. GISTIC Copy Number Analysis. S4. Somatic Variants in Relapsed/Refractory Childhood Solid Tumors (n=184 Patients with T/N WES). S5. Clinvar Pathogenic and Likely Germline Tumors(n=184 S6. Gene Lists. S7. Log2(TPM+1) Values for the 2,199 Most Variable Genes Expressed Across of RNA-seq (n=245). S8. Differential Expression Analysis Among Clusters. S9. Filtered COSMIC, Transcription Factors Potential Drug Targets...
<p>GISTIC Analysis of 184 Relapsed and Refractory Childhood Solid Tumors.</p>
<p>Neoantigen Landscape in Relapsed and Refractory Childhood Solid Tumors.</p>
<p>Additional Longitudinal Analysis of Relapsed and Refractory Childhood Solid Tumors.</p>
<div>Abstract<p>Children with treatment-refractory or relapsed (R/R) tumors face poor prognoses. As the genomic underpinnings driving R/R disease are not well defined, we describe here and transcriptomic landscapes of solid from 202 patients enrolled in Beat Childhood Cancer Consortium clinical trials. Tumor mutational burden (TMB) was elevated relative to untreated at diagnosis, one-third classified as having a pediatric high TMB. Prior chemotherapy exposure influenced landscape...
10006 Background: The major genomic profiling studies that have helped define the molecular landscapes of pediatric cancers typically focused on untreated at diagnosis. Despite improvements in overall survival for childhood cancers, patients with treatment-refractory or relapsed (R/R) solid tumors face a poor prognosis. underpinnings R/R disease are less well-characterized. Here, we describe integrated and transcriptomic analysis 250 from 202 children profiled within precision medicine...